Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 48Terminated 10Unknown 6Withdrawn 2Suspended 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 5Thoracic 2Gastrointestinal 2Dermatologic 2Breast 2Tumor-Agnostic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Recurrence 1Neoplasms 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Leukemia 1Hodgkin Disease 1

Interventions

Cyclophosphamide 170Rituximab 143Specimen Handling 82venetoclax 79fludarabine 78Vincristine 69obinutuzumab 67Doxorubicin 66Prednisone 65Biopsy 64Magnetic Resonance Spectroscopy 62zanubrutinib 52Lenalidomide 52Dexamethasone 49Methotrexate 43Cytarabine 43blinatumomab 40acalabrutinib 37Immunotherapy, Adoptive 37Bendamustine Hydrochloride 37Etoposide 32fludarabine phosphate 31ibrutinib 28glofitamab 28polatuzumab vedotin 26pirtobrutinib 24orelabrutinib 24Gemcitabine 23Injections 21Mercaptopurine 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × sargramostim × Lymphoid × Clear all
NCT05544968 2026-04-03

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

Medical College of Wisconsin

Phase 1 Recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Neoplasms, Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡